Desidustat (ZYAN1, ZYAN1-1001), an antianaemic drug candidate, is an orally active hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor (HIF-PHI) that stimulates erythropoiesis.
Storage Temp
Store at -20°C,Argon charged
Shipped In
Ice chest + Ice pads
Grade
Moligand™
Action Type
INHIBITOR
Mechanism of action
Inhibitor of egl-9 family hypoxia inducible factor 2
Product Description
Information
Desidustat Desidustat (ZYAN1, ZYAN1-1001), an antianaemic drug candidate, is an orally active hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor (HIF-PHI) that stimulates erythropoiesis.
Targets
PHD
In vivo
In BALB/c mice, a single dose treatment of desidustat attenuates the effect of lipopolysaccharide (LPS) - or turpentine oil-induced inflammation and increased serum erythropoietin (EPO), iron, and reticulocyte count, and decreases serum hepcidin levels. In turpentine oil-induced anemia in BALB/c mice, repeated dose desidustat treatment increases hemoglobin, RBC and hematocrit in a dose related manner. In female Lewis rats, treatment with desidustat markedly reduces PGPS-induced anemia and increases hemoglobin, red blood cell (RBC) and white blood cell (WBC) count, hematocrit, serum iron and spleen iron.
1.Patel H, Joharapurkar AA, Pandya VB, Patel VJ, Kshirsagar SG, Patel P, Gevriya B, Jain MR, Srinivas NR, Patel PR et al.. (2018) Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.. Xenobiotica, 48 (1):(37-44). [PMID:28042744][10.1021/op500134e]
2.Dhillon S. (2022) Desidustat: First Approval.. Drugs, 82 (11):(1207-1212). [PMID:35834123][10.1021/op500134e]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
